EXELIXIS, INC. EXEL

Latest FY: 2025 Healthcare Biotechnology
Market Price $51.26
Market Cap $12.72B
P/E Ratio 18.44
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑7.0% YoY
$2.32B
3-Yr CAGR: 12.9%
Net Income ↑50.1% YoY
$782.57M
Net Margin: 33.7%
Free Cash Flow ↑30.4% YoY
$875.84M
FCF Yield: 6.89%
EPS (Diluted) ↑58.0% YoY
$2.78
Basic: $2.88
Return on Equity Efficiency
36.2%
ROA: 26.5%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (EXEL)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2020: Revenue YoY (+0.0%) is identical to Net Income YoY (+0.0%). Verify the underlying Revenue and Net Income values for FY 2020 and FY 2019.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $191.5M $158.4M $-70.2M $-0.28 $206.3M $204.6M
FY 2017 $452.5M +136.3% $437.4M $154.2M +319.6% $0.49 +275.0% $165.6M $144.5M -29.4%
FY 2018 $853.8M +88.7% $827.5M $690.1M +347.4% $2.21 +351.0% $415.7M $382.4M +164.7%
FY 2019 $967.8M +13.3% $934.7M $321.0M -53.5% $1.02 -53.8% $527.0M $514.1M +34.4%
FY 2020 $967.8M 0.0% $597.7M $321.0M 0.0% $1.02 0.0% $527.0M $526.9M +2.5%
FY 2021 $1,435.0M +48.3% $1,382.1M $231.1M -28.0% $0.72 -29.4% $400.8M $336.6M -36.1%
FY 2022 $1,611.1M +12.3% $1,553.2M $182.3M -21.1% $0.56 -22.2% $362.6M $334.9M -0.5%
FY 2023 $1,830.2M +13.6% $1,757.7M $207.8M +14.0% $0.65 +16.1% $333.3M $292.9M -12.6%
FY 2024 $2,168.7M +18.5% $2,092.5M $521.3M +150.9% $1.76 +170.8% $700.0M $671.5M +129.3%
FY 2025 $2,320.1M +7.0% $2,236.4M $782.6M +50.1% $2.78 +58.0% $884.3M $875.8M +30.4%
$

Valuation

Market Price $51.26
Market Cap $12.72B
Enterprise Value N/A
P/E Ratio 18.44
P/B Ratio 5.96
FCF Yield 6.89%
Dividend Yield N/A
Shares Outstanding 251,355,100
%

Profitability & Margins

Gross Margin 96.39%
Operating Margin 37.59%
Net Margin 33.73%
Return on Equity (ROE) 36.21%
Return on Assets (ROA) 26.55%
Asset Turnover 0.79x
Revenue 3-Yr CAGR 12.93%
🛡️

Financial Health & Liquidity

Current Ratio 0.19
Cash Ratio 1.19
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $482.49M
Total Debt N/A
Book Value / Share $8.60
💧

Cash Flow Efficiency

Operating Cash Flow $884.27M
Capital Expenditures (CapEx) $8.43M
Free Cash Flow $875.84M
OCF / Revenue 38.11%
FCF / Revenue 37.75%
FCF 3-Yr CAGR 37.77%
🏷️

Per Share Metrics

EPS (Diluted) $2.78
EPS (Basic) $2.88
Dividends / Share N/A
Book Value / Share $8.60
EPS YoY Growth 57.95%
🏛️

Balance Sheet (FY 2025)

Total Assets $2.95B
Total Liabilities $703.49M
Stockholders' Equity $2.16B
Current Assets $75.60M
Current Liabilities $405.64M